Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
Treprostinil palmitil (TP), a prodrug of treprostinil, is being developed as an inhalation powder (TPIP) for the treatment of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD). In ongoing human clinical trials, TPIP is administer...
Main Authors: | Helena Gauani, Thomas Baker, Zhili Li, Vladimir S. Malinin, Walter R. Perkins, Eugene J. Sullivan, David Cipolla |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/3/934 |
Similar Items
-
Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2022-04-01) -
Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
by: Adam J. Plaunt, et al.
Published: (2021-01-01) -
In vitro Evaluation of Dry Powder Inhaler Devices of Corticosteroid Preparations
by: Gen Tamura, et al.
Published: (2012-01-01) -
BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™ in patients with pulmonary arterial hypertension
by: Leslie A. Spikes, et al.
Published: (2022-04-01) -
Preclinical Investigation of a Lipoglycopeptide Dry Powder Inhalation Therapy for the Treatment of Pulmonary MRSA Infection
by: Donna M. Konicek, et al.
Published: (2023-08-01)